Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer.
Blair McNamaraYifan ChangLevent MutluJustin HaroldAlessandro D SantinPublished in: Expert opinion on biological therapy (2023)
In patients with progressive, recurrent, or metastatic PD-L1 expressing cervical cancer, without contraindication to anti-VEGF therapy, the use of pembrolizumab with bevacizumab and standard chemotherapy with carboplatin and paclitaxel is warranted. There is no evidence to support the use of pembrolizumab for this population broadly, and no evidence to support its use in PD-L1 non-expressing tumors.
Keyphrases
- advanced non small cell lung cancer
- squamous cell carcinoma
- small cell lung cancer
- locally advanced
- metastatic colorectal cancer
- multiple sclerosis
- chemotherapy induced
- phase ii study
- stem cells
- randomized controlled trial
- radiation therapy
- clinical trial
- rectal cancer
- bone marrow
- cell therapy
- smoking cessation
- double blind